Detailed Information

Cited 0 time in webofscience Cited 1 time in scopus
Metadata Downloads

Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients

Authors
Yim, Sun YoungChun, Ho SooLee, Jae SeungLim, Ji-HwanKim, Tae HyungKim, Beom KyungKim, Seung UpPark, Jun YongAhn, Sang HoonKim, Gyoung MinWon, Jong YunSeo, Yeon SeokKim, Yun HwanUm, Soon HoKim, Do Young
Issue Date
Jan-2022
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Keywords
hepatocellular carcinoma; overall survival; progression-free survival; risk factor; transarterial chemoembolization
Citation
Cancers, v.14, no.2
Indexed
SCIE
SCOPUS
Journal Title
Cancers
Volume
14
Number
2
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/55236
DOI
10.3390/cancers14020385
ISSN
2072-6694
Abstract
Transarterial radioembolization (TARE) has become widely used in the treatment of HCC, one of the most common causes of cancer mortality worldwide. Here we investigated the long-term clinical outcomes of patients with hepatocellular carcinoma (HCC) treated with TARE in a multimedical center in Korea. A total of 149 patients treated with TARE from 2008–2014 were recruited. The pre-treatment HCC stage was classified according to the BCLC stage, of which C and D were defined as advanced HCC. Advanced HCC stage and Child–Turcotte–Pugh (CTP) score A were identified in 62 (42%) and 134 (90%) patients, respectively. Portal vein thrombosis (PVT) was identified in 58 patients (38.9%). The median time to progression (TTP) was 14 months, and the median overall survival (OS) and progression-free survival (PFS) were 18.6 and 8.9 months, respectively. The overall tumor response was 47%, and the disease control rate was 78%. OS and PFS differed significantly according to the presence of liver cirrhosis, extrahepatic metastasis, tumor response and curative treatment after TARE (all, p < 0.05). Multiple tumors and major PVT were other independent factors related to OS, while the des-gamma carboxy protein level predicted PFS (all, p < 0.05). Tumor size was an independent predictor of tumor response. TTP, OS and PFS all differed among BCLC stages.The serious adverse effect after TARE was clinically not significant. Therefore, TARE is safe and effective in treating early to advanced HCCs.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Radiology > 1. Journal Articles
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kim, Yun Hwan photo

Kim, Yun Hwan
Anam Hospital (Department of Radiology, Anam Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE